<unk>  is indicated for use in the treatment of pain and inflammation following cataract surgery. In the European Union<unk>  is also indicated for the reduction in the risk of postoperative macular edema associated with cataract surgery in people with diabetes.
Nepafenac
Tegaserod
Cimetidine
Melitracen
Lisocabtagene maraleucel
Coralmyn
Degmacyte
Lansoprazole